About Us
Science
Pipeline
- HMBD-001
- HMBD-501
News
Partnering
Patients
Contact
Join Us

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

by communications@hummingbirdbio.com on 11 September, 2023 in HMBD-001, Posters, Posters - 2023, Publications & Posters

<< Back to Publications

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

11 September, 2023

VIEW POSTER

<< Back to News

PubPosts-HMBD-001 RelatedNews-HMBD-001

Previous Reading

Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023

Next Reading

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Subscribe to our updates

*indicates required

*Email Address

*First Name

*Last Name

*Company

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

Leave a Reply Cancel reply